The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma Meeting Abstract


Authors: Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; Wilcox, R. A.; Steele, A.; Pandey, A.; Birrell, M. R.; Leeds, J. M.; Conley, P. B.; Michelson, G.; Coffey, G. P.; Curnutte, J. T.; Hamlin, P. A.
Abstract Title: The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837603031
PROVIDER: wos
Notes: Meeting Abstract: 1001 -- Source: Wos
MSK Authors
  1. Steven M Horwitz
    364 Horwitz
  2. Paul Hamlin
    174 Hamlin
Related MSK Work